Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN): 7 pipeline candidates · 2 upcoming catalysts · ~94 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
93.7 months
D/E 0.15 · 0% dilution
Lead: Approved
7 candidates
2 upcoming, next in ~1809d
0 buys · 5 sells (180d)
A transparent, data-derived signal for Day One Biopharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.2B
Cash
$197.1M
Quarterly Burn
$14.1M
Runway
93.7 mo
Revenue
$53.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| chemotherapeutic agent | Phase 3 |
| day301 | Phase 1 |
| emi-le | Phase 1 |
| jl18008 | Phase 1 |
| ojemda | Approved |
| tovorafenib | Phase 3 |
| tovorafenib drug | Phase 1 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
211
Total value held
$1.90B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,044,487 | $151.0M |
| vanguard capital management llc | 6,715,368 | $144.0M |
| fil ltd | 4,131,907 | $88.6M |
| kryger capital llc | 3,896,485 | $83.5M |
| deerfield management company, l.p. | 3,723,131 | $79.8M |
| perceptive advisors llc | 3,511,598 | $75.3M |
| jpmorgan chase & co | 3,134,753 | $67.1M |
| state street corp | 2,869,876 | $61.5M |
| balyasny asset management l.p. | 2,625,235 | $56.3M |
| aqr arbitrage llc | 2,462,154 | $52.8M |
Showing top 10 of 211 institutional holders of Day One Biopharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Day One Biopharmaceuticals, Inc.'s pipeline?
Day One Biopharmaceuticals, Inc. (DAWN) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Day One Biopharmaceuticals, Inc.'s lead drug candidate?
Day One Biopharmaceuticals, Inc.'s most advanced tracked candidate is chemotherapeutic agent (Phase 3) for Low-grade Glioma.
What is Day One Biopharmaceuticals, Inc.'s next catalyst?
Day One Biopharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versu" — expected June 1, 2031.
What is Day One Biopharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Day One Biopharmaceuticals, Inc. has approximately 93.7 months of cash runway.
What is Day One Biopharmaceuticals, Inc.'s market capitalization?
Day One Biopharmaceuticals, Inc.'s market capitalization is approximately $2.2B.
Get the full picture on Day One Biopharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.